Primary graft dysfunction after liver transplantation

Hepatobiliary and Pancreatic Diseases International

Volumn 13, Issue 2, 2014, Pages 125-137

  Chen, Xiao Bo ^a   Xu, Ming Qing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Graft function; Initial poor function; Liver transplantation; Primary graft dysfunction; Primary non function

Indexed keywords

NITRIC OXIDE; PROSTAGLANDIN E1; PROSTAGLANDIN E2; RECOMBINANT THROMBOMODULIN;

ALBUMIN DIALYSIS; BRAIN DEATH; CLINICAL FEATURE; COLD ISCHEMIA; FATTY LIVER; GRAFT RECIPIENT; HEART DEATH; HUMAN; HYPEROXIA; INCIDENCE; ISCHEMIA; LIVER GRAFT DYSFUNCTION; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); ORGAN DONOR; ORGAN PERFUSION; POSTOPERATIVE COMPLICATION; PRIMARY GRAFT DYSFUNCTION; REOPERATION; REPERFUSION INJURY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; GRAFT SURVIVAL; MORTALITY; PREDICTIVE VALUE; TIME; TREATMENT OUTCOME;

GRAFT SURVIVAL; HUMANS; LIVER TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PRIMARY GRAFT DYSFUNCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902598842     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(14)60023-0     Document Type: Review

References (75)

1. Foley DP, Fernandez LA, Leverson G, Chin LT, Krieger N, Cooper JT, et al. Donation after cardiac death: the University of Wisconsin experience with liver transplantation. Ann Surg 2005;242:724-731.
2. Sirivatanauksorn Y, Taweerutchana V, Limsrichamrern S, Kositamongkol P, Mahawithitwong P, Asavakarn S, et al. Analysis of donor risk factors associated with graft outcomes in orthotopic liver transplantation. Transplant Proc 2012;44: 320-323.
3. Pokorny H, Gruenberger T, Soliman T, Rockenschaub S, Längle F, Steininger R. Organ survival after primary dysfunction of liver grafts in clinical orthotopic liver transplantation. Transpl Int 2000;13:S154-157.
4. Uemura T, Randall HB, Sanchez EQ, Ikegami T, Narasimhan G, McKenna GJ, et al. Liver retransplantation for primary nonfunction: analysis of a 20-year single-center experience. Liver Transpl 2007;13:227-233.
5. Novelli G, Morabito V, Lai Q, Levi Sandri GB, Melandro F, Pugliese F, et al. Glasgow coma score and tumor necrosis factor a as predictive criteria for initial poor graft function. Transplant Proc 2012;44:1820-1825.
6. Ploeg RJ, D'Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation--a multivariate analysis. Transplantation 1993;55:807-813.
7. Nanashima A, Pillay P, Verran DJ, Painter D, Nakasuji M, Crawford M, et al. Analysis of initial poor graft function after orthotopic liver transplantation: experience of an australian single liver transplantation center. Transplant Proc 2002;34:1231-1235.
8. Dhillon N, Walsh L, Krüger B, Ward SC, Godbold JH, Radwan M, et al. A single nucleotide polymorphism of Tolllike receptor 4 identifes the risk of developing graft failure after liver transplantation. J Hepatol 2010;53:67-72.
9. Broering DC, Topp S, Schaefer U, Fischer L, Gundlach M, Sterneck M, et al. Split liver transplantation and risk to the adult recipient: analysis using matched pairs. J Am Coll Surg 2002;195:648-657.
10. Heise M, Settmacher U, Pftzmann R, Wünscher U, Müller AR, Jonas S, et al. A survival-based scoring-system for initial graft function following orthotopic liver transplantation. Transpl Int 2003;16:794-800.
11. Cieślak B, Lewandowski Z, Urban M, Ziarkiewicz-Wróblewska B, Krawczyk M. Microvesicular liver graft steatosis as a risk factor of initial poor function in relation to suboptimal donor parameters. Transplant Proc 2009;41:2985-2988.
12. Nemes B, Gelley F, Zádori G, Piros L, Perneczky J, Kóbori L, et al. Outcome of liver transplantation based on donor graft quality and recipient status. Transplant Proc 2010;42:2327-2330.
13. González FX, Rimola A, Grande L, Antolin M, Garcia-Valdecasas JC, Fuster J, et al. Predictive factors of early postoperative graft function in human liver transplantation. Hepatology 1994;20:565-573.
14. Corradini SG, Elisei W, De Marco R, Siciliano M, Iappelli M, Pugliese F, et al. Preharvest donor hyperoxia predicts good early graft function and longer graft survival after liver transplantation. Liver Transpl 2005;11:140-151.
15. Olinga P, Maring JK, Groothuis GM, Kranenburg K, Merema M, Hof IH, et al. Value of the in vitro or in vivo monoethylglycinexylidide test for predicting liver graft function. Transplantation 1997;64:60-65.
16. Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of a current defnition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl 2010;16:943-949.
17. Lock JF, Malinowski M, Schwabauer E, Martus P, Pratschke J, Seehofer D, et al. Initial liver graft function is a reliable predictor of tacrolimus trough levels during the frst post-transplant week. Clin Transplant 2011;25:436-443.
18. Stockmann M, Lock JF, Malinowski M, Seehofer D, Puhl G, Pratschke J, et al. How to defne initial poor graft function after liver transplantation? - a new functional defnition by the LiMAx test. Transpl Int 2010;23:1023-1032.
19. Defamie V, Cursio R, Le Brigand K, Moreilhon C, Saint-Paul MC, Laurens M, et al. Gene expression profling of human liver transplants identifes an early transcriptional signature associated with initial poor graft function. Am J Transplant 2008;8:1221-1236.
20. Máthé Z, Paul A, Molmenti EP, Vernadakis S, Klein CG, Beckebaum S, et al. Liver transplantation with donors over the expected lifespan in the model for end-staged liver disease era: is Mother Nature punishing us? Liver Int 2011;31: 1054-1061.
21. Takaya S, Doyle H, Todo S, Irish W, Fung JJ, Starzl TE. Reduction of primary nonfunction with prostaglandin E1 after clinical liver transplantation. Transplant Proc 1995;27: 1862-1867.
22. Escorsell À, Mas A, Fernández J, García-Valdecasas JC. Limitations of use of the noninvasive clearance of indocyanine green as a prognostic indicator of graft function in liver transplantation. Transplant Proc 2012;44:1539-1541.
23. Monbaliu D, Libbrecht L, De Vos R, Vekemans K, Walter H, Liu Q, et al. The extent of vacuolation in non-heart-beating porcine donor liver grafts prior to transplantation predicts their viability. Liver Transpl 2008;14:1256-1265.
24. Kremers WK, van IJperen M, Kim WR, Freeman RB, Harper AM, Kamath PS, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 2004;39:764-769.
25. Johnson SR, Alexopoulos S, Curry M, Hanto DW. Primary nonfunction (PNF) in the MELD Era: An SRTR database analysis. Am J Transplant 2007;7:1003-1009.
26. DAlessandro AM, Fernandez LA, Chin LT, Shames BD, Turgeon NA, Scott DL, et al. Donation after cardiac death: the University of Wisconsin experience. Ann Transplant 2004;9:68-71.
27. Brokelman W, Stel AL, Ploeg RJ. Risk factors for primary dysfunction after liver transplantation in the University of Wisconsin solution era. Transplant Proc 1999;31:2087-2090.
28. Rull R, Vidal O, Momblan D, González FX, López-Boado MA, Fuster J, et al. Evaluation of potential liver donors: limits imposed by donor variables in liver transplantation. Liver Transpl 2003;9:389-393.
29. Uzun MA, Koksal N, Kadioglu H, Gunerhan Y, Aktas S, Dursun N, et al. Effects of N-acetylcysteine on regeneration following partial hepatectomy in rats with nonalcoholic fatty liver disease. Surg Today 2009;39:592-597.
30. Ureña MA, Ruiz-Delgado FC, González EM, Segurola CL, Romero CJ, García IG, et al. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. Transplant Proc 1998;30:3288-3291.
31. Teramoto K, Bowers JL, Kruskal JB, Clouse ME. Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat. Transplantation 1993;56:1076-1082.
32. Gordon Burroughs S, Busuttil RW Optimal utilization of extended hepatic grafts. Surg Today 2009;39:746-751.
33. Lawal A, Florman S, Fiel MI, Gordon R, Bromberg J, Schiano TD. Identifcation of ultrastructural changes in liver allografts of patients experiencing primary nonfunction. Transplant Proc 2005;37:4339-4342.
34. Silva MA, Mirza DF, Murphy N, Richards DA, Reynolds GM, Wigmore SJ, et al. Intrahepatic complement activation, sinusoidal endothelial injury, and lactic acidosis are associated with initial poor function of the liver after transplantation. Transplantation 2008;85:718-725.
35. Ciria R, Briceno J, Rufan S, Luque A, Lopez-Cillero P. Donation after cardiac death: where, when, and how? Transplant Proc 2012;44:1470-1474.
36. Nafdi O, Letourneau R, Willems BE, Lapointe RW. Reuse of liver graft from a brain dead recipient. Clin Transplant 2007;21:773-776.
37. Briceño J, Ciria R, de la Mata M, Rufán S, López-Cillero P. Prediction of graft dysfunction based on extended criteria donors in the model for end-stage liver disease score era. Transplantation 2010;90:530-539.
38. Cameron AM, Ghobrial RM, Yersiz H, Farmer DG, Lipshutz GS, Gordon SA, et al. Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg 2006;243:748-755.
39. Silberhumer GR, Pokorny H, Hetz H, Herkner H, Rasoul-Rockenschaub S, Soliman T, et al. Combination of extended donor criteria and changes in the Model for End-Stage Liver Disease score predict patient survival and primary dysfunction in liver transplantation: a retrospective analysis. Transplantation 2007;83:588-592.
40. Corradini SG, Micheletta F, Natoli S, Iappelli M, Di Angelantonio E, De Marco R, et al. High preoperative recipient plasma 7beta-hydroxycholesterol is associated with initial poor graft function after liver transplantation. Liver Transpl 2005;11:1494-1504.
41. Chui AK, Shi LW, Rao AR, Anasuya A, Hagl C, Pillay P, et al. Primary graft dysfunction after liver transplantation. Transplant Proc 2000;32:2219-2220.
42. Chen H, Peng CH, Shen BY, Deng XX, Shen C, Xie JJ, et al. Multi-factor analysis of initial poor graft function after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 2007;6:141-146.
43. Weiss S, Kotsch K, Francuski M, Reutzel-Selke A, Mantouvalou L, Klemz R, et al. Brain death activates donor organs and is associated with a worse I/R injury after liver transplantation. Am J Transplant 2007;7:1584-1593.
44. Lisman T, Leuvenink HG, Porte RJ, Ploeg RJ. Activation of hemostasis in brain dead organ donors: an observational study. J Thromb Haemost 2011;9:1959-1965.
45. Bispo M, Marcelino P, Marques HP, Martins A, Perdigoto R, Aguiar MJ, et al. Domino versus deceased donor liver transplantation: association with early graft function and perioperative bleeding. Liver Transpl 2011;17:270-278.
46. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783-790.
47. Braat AE, Blok JJ, Putter H, Adam R, Burroughs AK, Rahmel AO, et al. The Eurotransplant donor risk index in liver transplantation: ET-DRI. Am J Transplant 2012;12:2789-2796.
48. Lang JD Jr, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK, et al. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest 2007;117:2583-2591.
49. Taki-Eldin A, Zhou L, Xie HY, Chen KJ, Yu D, He Y, et al. Triiodothyronine attenuates hepatic ischemia/reperfusion injury in a partial hepatectomy model through inhibition of proinfammatory cytokines, transcription factors, and adhesion molecules. J Surg Res 2012;178:646-656.
50. Koçbiyik A, Demirhan B, Sevmis S, Budakoglu I, Karakayali H, Haberal M. Role of postreperfusion subcapsular wedge biopsies in predicting initially poor graft function after liver transplantation. Transplant Proc 2009;41:2747-2748.
51. Cavalcanti AB, De Vasconcelos CP, Perroni de Oliveira M, Rother ET, Ferraz L Jr. Prostaglandins for adult liver transplanted patients. Cochrane Database Syst Rev 2011;9: CD006006.
52. Monbaliu D, de Vries B, Crabbé T, van Heurn E, Verwaest C, Roskams T, et al. Liver fatty acid-binding protein: an early and sensitive plasma marker of hepatocellular damage and a reliable predictor of graft viability after liver transplantation from non-heart-beating donors. Transplant Proc 2005;37:413-416.
53. Shigeta T, Matsuno N, Obara H, Mizunuma H, Kanazawa H, Tanaka H, et al. Functional recovery of donation after cardiac death liver graft by continuous machine perfusion preservation in pigs. Transplant Proc 2012;44:946-947.
54. Obara H, Matsuno N, Enosawa S, Shigeta T, Huai-Che H, Hirano T, et al. Pretransplant screening and evaluation of liver graft viability using machine perfusion preservation in porcine transplantation. Transplant Proc 2012;44:959-961.
55. Qing DK, Dong JH, Han BL, Chen XR. Cold preservation of pig liver grafts with warm ischemia and pentoxifylline-UW solution. Arch Med Res 2006;37:449-455.
56. Zheng SG, Feng XB, He ZP, Qing DK, Leng JJ, Dong JH. Experimental study on tolerance time limits from warm ischemia to cold preservation of liver grafts. Zhonghua Gan Zang Bing Za Zhi 2006;14:250-254.
57. Jamieson NV, Sundberg R, Lindell S, Claesson K, Moen J, Vreugdenhil PK, et al. Preservation of the canine liver for 24-48 hours using simple cold storage with UW solution. Transplantation 1988;46:517-522.
58. Sirivatanauksorn Y, Taweerutchana V, Limsrichamrern S, Kositamongkol P, Mahawithitwong P, Asavakarn S, et al. Recipient and perioperative risk factors associated with liver transplant graft outcomes. Transplant Proc 2012;44:505-508.
59. Lai Q, Molinaro A, Mennini G, Nudo F, Morabito V, Corradini SG, et al. Preoperative donor scores and postoperative early measures of graft function: relevance to the outcome of liver transplantation. Transplant Proc 2010;42:1209-1211.
60. Ijtsma AJ, van der Hilst CS, de Boer MT, de Jong KP, Peeters PM, Porte RJ, et al. The clinical relevance of the anhepatic phase during liver transplantation. Liver Transpl 2009;15: 1050-1055.
61. Driscoll DF, Bistrian BR, Jenkins RL, Randall S, Dzik WH, Gerson B, et al. Development of metabolic alkalosis after massive transfusion during orthotopic liver transplantation. Crit Care Med 1987;15:905-908.
62. Wu JF, Wu RY, Chen J, Ou-Yang B, Chen MY, Guan XD. Early lactate clearance as a reliable predictor of initial poor graft function after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 2011;10:587-592.
63. Bassanello M, De Palo EF, Lancerin F, Vitale A, Gatti R, Montin U, et al. Growth hormone/insulin-like growth factor 1 axis recovery after liver transplantation: a preliminary prospective study. Liver Transpl 2004;10:692-698.
64. Bärthel E, Rauchfuss F, Hoyer H, Habrecht O, Jandt K, Götz M, et al. Impact of stable PGI2 analog iloprost on early graft viability after liver transplantation: a pilot study. Clin Transplant 2012;26:E38-47.
65. Webber A, Hambleton J, Chami A, Bang H, Seshan S, Sharma A, et al. Mean arterial blood pressure while awaiting kidney transplantation is associated with the risk of primary nonfunction. Transplantation 2012;93:54-60.
66. Gao ZH. Seeking beyond rejection: an update on the differential diagnosis and a practical approach to liver allograft biopsy interpretation. Adv Anat Pathol 2009;16:97-117.
67. Wisecaver JL, Radio SJ, Shaw BW Jr, Langnas AN, Markin RS. Intrahepatic arteriopathy associated with primary nonfunction of liver allografts. Hum Pathol 1994;25:960-963.
68. Abbas R, Kombu RS, Dignam D, Gunning W, Stulberg JJ, Brunengraber H, et al. Polyethylene glycol modifed-albumin enhances the cold preservation properties of University of Wisconsin solution in rat liver and a hepatocyte cell line. J Surg Res 2010;164:95-104.
69. Tzimas GN, Afshar M, Emadali A, Chevet E, Vali H, Metrakos PP. Correlation of cell necrosis and tissue calcifcation with ischemia/reperfusion injury after liver transplantation. Transplant Proc 2004;36:1766-1768.
70. Aydin Z, Mallat MJ, Schaapherder AF, van Zonneveld AJ, van Kooten C, Rabelink TJ, et al. Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant 2012;12: 1793-1800.
71. Novelli G, Annesini MC, Morabito V, Cinti P, Pugliese F, Novelli S, et al. Cytokine level modifcations: molecular adsorbent recirculating system versus standard medical therapy. Transplant Proc 2009;41:1243-1248.
72. Kashiwadate T, Miyagi S, Hara Y, Akamatsu Y, Kawagishi N, Sekiguchi S, et al. Recombinant human soluble thrombomodulin (ART-123) prevents warm ischemia-reperfusion injury in liver grafts from non-heart-beating donors. Transplant Proc 2012;44:369-372.
73. Zaim M, Karaman S, Cetin G, Isik S. Donor age and long-term culture affect differentiation and proliferation of human bone marrow mesenchymal stem cells. Ann Hematol 2012;91:1175-1186.
74. Pan GZ, Yang Y, Zhang J, Liu W, Wang GY, Zhang YC, et al. Bone marrow mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injuries via inactivation of the MEK/ ERK signaling pathway in rats. J Surg Res 2012;178:935-948.
75. Pokorny H, Langer F, Herkner H, Schernberger R, Plöchl W, Soliman T, et al. Influence of cumulative number of marginal donor criteria on primary organ dysfunction in liver recipients. Clin Transplant 2005;19:532-536.